// App-Quantinova.ai

1888 : Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 12 Months in Subgroups of Glucocorticoid-Treated Individuals

Researchers

Presenter

  • Kenneth Saag

Principal Investigators

  • N Pannacciulli

  • P Geusens

  • J Adachi

  • Eric Lespessailles

  • J Malouf

  • O Messina

  • AT Wang

  • Rachel B. Wagman

  • WF Lems

Medical Centers

  • University of Alabama, Birmingham, AL

  • Amgen Inc, Thousand Oaks, CA

  • Maastricht University, Maastricht, Netherlands

  • McMaster University, Hamilton, ON, Canada

  • University Hospital Orleans, Orleans, France

  • Hospital De Sant Pau, Barcelona, Spain

  • Cosme Argerich Hospital, Buenos Aires, Argentina

  • VU University Medical Center, Amsterdam, Netherlands

Locations

  • United States

  • Netherlands

  • Canada

  • France

  • Spain

  • Argentina

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Guanylate cyclase 2C

  • Bone Mineral Density

Drug/Treatment

  • Glucocorticoid

  • Risedronate sodium

  • Prednisone

  • Ergocalciferol

  • Denosumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved